Immix Biopharma
$8.62
26
-$0.49-5.38% Today
Statistics
Day High
9.6
Day Low
8.54
52W High
11.61
52W Low
1.34
Volume
671,828
Avg. Volume
894,922
Mkt Cap
289.44M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
3JunExpected
Expected EPS
-0.2075
Actual EPS
N/A
Financials
-Profit Margin
Unprofitable0Revenue
-43.23MNet Income
Analyst Ratings
$18.00Average Price Target
The highest estimate is 23.00.
From 4 ratings within the last 6 months. This is not an investment recommendation.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy 75%
Hold 25%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow IMMX. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.29B
Alnylam Pharmaceuticals
ALNY
Mkt Cap60.25B
Ionis Pharmaceuticals
IONS
Mkt Cap12.03B
Incyte
INCY
Mkt Cap18.35B
Exelixis
EXEL
Mkt Cap10.41B
Novartis
NVS
Mkt Cap237.61B
Gilead Sciences
GILD
Mkt Cap148.78B
AMGEN
AMGN
Mkt Cap160.66B
About
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.
Show more...
CEO
Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D.
Employees
18
Country
US
ISIN
US45258H1068
Listings
0 Comments
Share your thoughts
FAQ
What is Immix Biopharma stock price today?▼
The current price of IMMX is $8.62 USD — it has decreased by -5.38% in the past 24 hours. Watch Immix Biopharma stock price performance more closely on the chart.
What is Immix Biopharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Immix Biopharma stocks are traded under the ticker IMMX.
Is Immix Biopharma stock price growing?▼
IMMX stock has fallen by -3.25% compared to the previous week, the month change is a +6.82% rise, over the last year Immix Biopharma has showed a +435.4% increase.
What is Immix Biopharma market cap?▼
Today Immix Biopharma has the market capitalization of 289.44M
When is the next Immix Biopharma earnings date?▼
Immix Biopharma is going to release the next earnings report on June 03, 2026.
What were Immix Biopharma earnings last quarter?▼
IMMX earnings for the last quarter are -0.27 USD per share, whereas the estimation was -0.15 USD resulting in a -86.21% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Immix Biopharma revenue for the last year?▼
Immix Biopharma revenue for the last year amounts to 0 USD.
What is Immix Biopharma net income for the last year?▼
IMMX net income for the last year is -43.23M USD.
How many employees does Immix Biopharma have?▼
As of April 01, 2026, the company has 18 employees.
In which sector is Immix Biopharma located?▼
Immix Biopharma operates in the Health Care sector.
When did Immix Biopharma complete a stock split?▼
Immix Biopharma has not had any recent stock splits.
Where is Immix Biopharma headquartered?▼
Immix Biopharma is headquartered in Los Angeles, US.